Unibest
← Back to patent-cliff list

Plinabulin

Tier C — Watch / trade

Plinabulin

Nereus Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Natural product / extract
Type

Targets:GEF-H1, Tubulin

Indications (approved):Non-small cell lung cancer, Neutropenia, Multiple myeloma, Lung cancer, Small cell lung cancer, Merkel细胞癌, Bladder cancer, Melanoma

Regional status

US
Phase III
2015-12-01
EU
Phase III
2018-05-29
China
Phase III
2015-12-01
Japan
-

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 2 · Total yield 0.80 mg (Plinabulin)
PLIN-0013027-05-2PLIN-002100-52-7PLIN-00330166-30-4PLIN-004714273-83-3API · Plinabulin
CodeCAS No.Intermediate
PLIN-0013027-05-21,4-diacetylpiperazine-2,5-dione
PLIN-002100-52-7Availablebenzaldehyde
PLIN-00330166-30-4(Z)-1-acetyl-3-benzylidenepiperazine-2,5-dione
PLIN-004714273-83-35-(tert-butyl)-1H-imidazole-4-carbaldehyde
OptimisedRoute 2Steps 6 · Total yield 1.59 g (Plinabulin)
PLIN-0013027-05-2PLIN-002100-52-7PLIN-004714273-83-3PLIN-00517094-34-7PLIN-00629509-07-7PLIN-00775-12-7PLIN-00851721-21-2PLIN-00951721-22-3PLIN-010714273-84-4API · Plinabulin
CodeCAS No.Intermediate
PLIN-0013027-05-21,4-diacetylpiperazine-2,5-dione
PLIN-002100-52-7Availablebenzaldehyde
PLIN-004714273-83-35-(tert-butyl)-1H-imidazole-4-carbaldehyde
PLIN-00517094-34-7ethyl 4,4-dimethyl-3-oxopentanoate
PLIN-00629509-07-7ethyl 2-chloro-4,4-dimethyl-3-oxopentanoate
PLIN-00775-12-7formamide
PLIN-00851721-21-2ethyl 5-(tert-butyl)-1H-imidazole-4-carboxylate
PLIN-00951721-22-3(5-(tert-butyl)-1H-imidazol-4-yl)methanol
PLIN-010714273-84-4(Z)-1-acetyl-3-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione

Frequently asked questions

What are the approved indications of Plinabulin?

Approved indications include: Non-small cell lung cancer, Neutropenia, Multiple myeloma, Lung cancer, Small cell lung cancer, Merkel细胞癌, Bladder cancer, Melanoma.

When does the Plinabulin patent expire?

No public expiry year is available for Plinabulin yet; this page updates once verified.

How many synthesis routes are recorded for Plinabulin?

2 synthesis routes are recorded; the shortest is 2 steps with 0.80 mg (Plinabulin) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Plinabulin intermediates?

1 intermediate CAS of Plinabulin are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Plinabulin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-10